000			02164 a2200577 4500
005			20250517011512.0
264		0	_c20160119
008			201601s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-014-0199-x _2doi
040			_aNLM _beng _cNLM
100	1		_aPetrylak, Daniel P
245	0	0	_aPhase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. _h[electronic resource]
260			_bInvestigational new drugs _cApr 2015
300			_a397-408 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aDehydroepiandrosterone Sulfate _xblood
650	0	4	_aDisease Progression
650	0	4	_aDisease-Free Survival
650	0	4	_aDocetaxel
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aHumans
650	0	4	_aImidazoles _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNaphthalenes _xadministration & dosage
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aProstate-Specific Antigen
650	0	4	_aProstatic Neoplasms, Castration-Resistant _xdrug therapy
650	0	4	_aSteroid 17-alpha-Hydroxylase _xantagonists & inhibitors
650	0	4	_aTaxoids _xadministration & dosage
650	0	4	_aTestosterone _xblood
700	1		_aGandhi, Jitendra G
700	1		_aClark, William R
700	1		_aHeath, Elisabeth
700	1		_aLin, Jianqing
700	1		_aOh, William K
700	1		_aAgus, David B
700	1		_aCarthon, Bradley
700	1		_aMoran, Susan
700	1		_aKong, Ning
700	1		_aSuri, Ajit
700	1		_aBargfrede, Michael
700	1		_aLiu, Glenn
773	0		_tInvestigational new drugs _gvol. 33 _gno. 2 _gp. 397-408
856	4	0	_uhttps://doi.org/10.1007/s10637-014-0199-x _zAvailable from publisher's website
999			_c24503561 _d24503561